thrm-8k_20190725.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 25, 2019

 

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

 

Michigan

 

0-21810

 

95-4318554

 

 

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

21680 Haggerty Road, Northville, MI

48167

 

 

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (248) 504-0500

Former name or former address, if changed since last report: N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, no par value

THRM

The NASDAQ Global Select Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On July 25, 2019, Gentherm Incorporated (the “Company”) publicly announced its financial results for the second quarter of 2019. A copy of the Company’s news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On July 25, 2019 at 8:00 a.m. Eastern Time, the Company will host a conference call to discuss the second quarter of 2019 financial results. A copy of the supplemental materials that will be used during the conference call is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 2.02 and the attached exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

 

Exhibit 99.1

  

Company news release dated July 25, 2019 concerning financial results

 

 

 

Exhibit 99.2

  

Supplemental materials dated July 25, 2019

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GENTHERM INCORPORATED

 

 

 

 

By:

 

/s/ Wayne Kauffman

 

 

 

Wayne Kauffman

 

 

 

Vice President and General Counsel

Date:  July 25, 2019

 

 

 

 

thrm-ex991_6.htm

 

Exhibit 99.1

 

 

Gentherm Reports 2019 Second Quarter Results

 

Revenue Performance Reflects Challenging Automotive Environment

Achieved Highest Gross Margin Rate in 5 Quarters

Reduced Operating Expenses by 14%

Updates 2019 Revenue and Gross Margin Guidance

 

NORTHVILLE, Michigan, July 25, 2019 /Global Newswire/ - Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management technologies, today announced its financial results for the second quarter ended June 30, 2019.

Second Quarter Highlights

 

Product revenues of $243.3 million decreased 8.7% from $266.4 million in the 2018 second quarter

 

Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues decreased 1.9% year over year

 

GAAP diluted earnings per share was $0.08 as compared to $0.45 for the prior-year period

 

Adjusted earnings per share (see table herein) was $0.47. Adjusted earnings per share in the prior-year period was $0.58

 

Secured automotive new business awards totaling $260 million

 

Repurchased $25 million of the Company’s stock

Phil Eyler, the Company's President and CEO, said “We continued to make progress with our focused growth strategy, achieved our highest gross margin rate in five quarters and reduced operating expenses by 14 percent from a year ago. Our Medical business grew double digits in the quarter as we successfully added Stihler products to our portfolio.”

 

“In Automotive, we secured over $2.2 billion of new awards from top auto makers around the world in the last six quarters and consistently outperformed actual light vehicle production in our key markets. However, the production environment continues to deteriorate, putting downward pressure on our revenue growth trajectory. While we are reducing our revenue guidance for 2019, we are tightening our gross margin range and maintaining our profitability guidance as we continue to improve our cost performance through the Fit-for-Growth program,” continued Eyler.

2019 Second Quarter Financial Review

Product revenues for the second quarter of 2019 of $243.3 million declined $23.1 million, or 8.7%, as compared to the prior-year period. Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues declined 1.9% year over year.

 

Automotive revenues declined 5.5% year over year. All product categories saw revenue declines except Battery Thermal Management (BTM) and Other Automotive. Adjusting for foreign currency translation, organic Automotive revenues decreased 3.0% year over year. When compared with IHS Markit's mid-April forecast for the second quarter of 2019, actual light vehicle production was approximately 4 percentage points below forecast. In addition, when compared to the second quarter of 2018, actual global light vehicle production declined by 8%.

 


 

 

The revenue decline in the Industrial segment resulted from the absence of revenue in this year’s second quarter from the divested Cincinnati Sub-Zero (CSZ) industrial chamber business and lower sales in the Global Power Technologies (GPT) business, which has been classified as “assets held for sale. The decline was partially offset by higher medical revenue. Gentherm Medical revenue grew 30.7% year over year as a result of the Stihler acquisition that occurred in the first quarter of 2019, as well as higher Blanketrol sales.

See the “Revenue by Product Category” table included below for additional detail.

The gross margin rate increased to 29.9% in the current-year period, a 100-basis point improvement over the prior-year period, primarily as a result of supplier cost reductions, higher labor productivity and Fit-for-Growth cost reduction initiatives. These were partially offset by annual customer price reductions, wage inflation, tariffs, as well as the negative fixed cost leverage from lower unit volume. On a sequential basis, the gross margin rate improved 70 basis points.

Net research and development (R&D) expenses of $19.3 million in the second quarter of 2019 decreased $1.8 million, or 8.5%, year over year as a direct result of the Company’s focused portfolio and Fit-for-Growth cost reduction initiatives.

Selling, general and administrative (SG&A) expenses of $31.8 million in the second quarter of 2019 decreased $2.4 million, or 7.1%, versus the prior-year period. The year-over-year decline was primarily driven by the sale of the CSZ industrial chambers business and the impact of the Fit-for-Growth cost reduction initiatives.

During the quarter, the Company recognized $1.2 million in restructuring expenses which resulted from completed actions associated with its Fit-for-Growth initiatives. Total implemented actions to date are expected to deliver annualized savings of approximately $42 million. The Company has identified a total of $68 million of savings against its annualized target of $75 million by 2021.

As described more fully in the table included below, “Reconciliation of Net Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $32.2 million during the second quarter of 2019 compared to $35.5 million in the prior year, a year-over-year decrease of $3.3 million or 9.5%.

Income tax expense in the 2019 second quarter was $5.5 million, as compared with $3.1 million in the prior-year period. Adjusting for the $9.9 million non-deductible impairment loss, the effective tax rate for the quarter was 30.5%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.

GAAP diluted earnings per share for the second quarter of 2019 was $0.08 compared with $0.45 for the prior-year period. Adjusted diluted earnings per share, excluding restructuring expenses, impairment charges, unrealized currency gain, and other impacts (see table herein), was $0.47. Adjusted diluted earnings per share in the prior-year period was $0.58.

Guidance

Based on the Company’s second quarter results and the challenging macroeconomic environment, Gentherm is updating its revenue and gross margin guidance, while maintaining all other guidance metrics, for 2019 excluding the impact of foreign currency translation, divested assets and assets held for sale as follows:

 

Product revenues are expected to grow between 0% and 2%

 

Operating expenses between 19% and 20% of product revenues

 


 

 

 

Gross margin rate between 29% and 30%

 

Adjusted EBITDA between 14% and 15% of product revenue

 

Full-year effective tax rate between 28% and 30%

 

Capital expenditures between $40 and $50 million

Conference Call

 

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13692030.

 

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

A telephonic replay will be available approximately 2 hours after the call until 11:59 pm Eastern Time on August 8, 2019. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13692030.

 

 

Investor Relations Contact
Yijing Brentano

investors@gentherm.com
(248) 308-1702

 

Media Contact

Melissa Fischer

media@gentherm.com

248.289.9702

 

About Gentherm

 

Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 13,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

 

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this

 


 

 

release are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs.  Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, new competitors may arise or customers may develop their own products to replace the Company’s products, customer preferences for end products may shift, the Company may lose suppliers or customers, market acceptance of the Company’s existing or new products may decrease, currency exchange rates may change unfavorably, pricing pressures from customers may increase, current and projected future declines in automobile production may have an adverse impact, the macroeconomic environment may present adverse conditions, additional financing requirements may not be available, the Company’s workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, our customers may not accept pass-through of new tariff costs, additional tariffs may be implemented, cost-savings measures may not be achievable or may need to be reversed, assets held for sale may not be sold quickly or at all, the Company may be unable to repurchase its shares of common stock at favorable prices or at all, due to market conditions, applicable legal requirements, debt covenants or other restrictions, compliance with covenants and other restrictions under the Company’s credit facility, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results.

 

The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent quarterly reports, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof. 

 

Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

 

 

 

# # # #


 


 

 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended

June 30,

 

 

 

 

2019

 

 

2018(1)

 

 

2019

 

 

  2018(1)

 

 

Product revenues

 

$

243,326

 

 

$

266,400

 

 

$

501,247

 

 

$

530,986

 

 

Cost of sales

 

 

170,612

 

 

 

189,308

 

 

 

353,226

 

 

 

372,652

 

 

Gross margin

 

 

72,714

 

 

 

77,092

 

 

 

148,021

 

 

 

158,334

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net research and development expenses

 

 

19,255

 

 

 

21,022

 

 

 

38,152

 

 

 

44,326

 

 

Selling, general and administrative expenses

 

 

31,829

 

 

 

34,262

 

 

 

64,442

 

 

 

70,686

 

 

Acquisition transaction expense

 

 

342

 

 

 

 

 

 

380

 

 

 

 

 

Restructuring expenses

 

 

1,231

 

 

 

6,215

 

 

 

3,145

 

 

 

7,080

 

 

Total operating expenses

 

 

52,657

 

 

 

61,499

 

 

 

106,119

 

 

 

122,092

 

 

Operating income

 

 

20,057

 

 

 

15,593

 

 

 

41,902

 

 

 

36,242

 

 

Interest expense

 

 

(1,240

)

 

 

(1,240

)

 

 

(2,608

)

 

 

(2,420

)

 

Foreign currency (loss) gain

 

 

(804

)

 

 

5,174

 

 

 

(601

)

 

 

596

 

 

Gain on sale of business

 

 

 

 

 

 

 

 

4,970

 

 

 

 

 

Impairment loss

 

 

(9,885

)

 

 

 

 

 

(20,369

)

 

 

 

 

Other income

 

 

171

 

 

 

215

 

 

 

314

 

 

 

1,326

 

 

Earnings before income tax

 

 

8,299

 

 

 

19,742

 

 

 

23,608

 

 

 

35,744

 

 

Income tax expense

 

 

5,548

 

 

 

3,083

 

 

 

12,443

 

 

 

6,119

 

 

Net income

 

$

2,751

 

 

$

16,659

 

 

$

11,165

 

 

$

29,625

 

 

Basic earnings per share

 

$

0.08

 

 

$

0.46

 

 

$

0.33

 

 

$

0.81

 

 

Diluted earnings per share

 

$

0.08

 

 

$

0.45

 

 

$

0.33

 

 

$

0.81

 

 

Weighted average number of shares – basic

 

 

33,441

 

 

 

36,523

 

 

 

33,508

 

 

 

36,560

 

 

Weighted average number of shares – diluted

 

 

33,574

 

 

 

36,667

 

 

 

33,651

 

 

 

36,663

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)  Certain reclassifications of prior year’s amounts have been made to conform with the current year’s presentation

 

 

 


 


 

 

 

GENTHERM INCORPORATED

REVENUE BY PRODUCT CATEGORY

(Unaudited, in thousands)

 

 

 

Three Months Ended
June 30,

 

 

 

 

 

 

Six Months Ended
June 30,

 

 

 

 

 

 

 

2019

 

 

2018(1)

 

 

  % Diff.

 

2019

 

 

2018(1)

 

 

% Diff.

Climate Controlled Seat (CCS)

 

$

88,437

 

 

$

90,395

 

 

 

(2.1)%

 

 

$

182,791

 

 

$

178,613

 

 

 

2.3 %

 

Seat Heaters

 

 

73,628

 

 

 

80,176

 

 

 

(8.2)%

 

 

 

147,548

 

 

 

164,396

 

 

 

(10.2)%

 

Steering Wheel Heaters

 

 

16,029

 

 

 

17,540

 

 

 

(8.6)%

 

 

 

32,999

 

 

 

35,097

 

 

 

(6.0)%

 

Automotive Cables

 

 

22,205

 

 

 

25,645

 

 

 

(13.4)%

 

 

 

45,955

 

 

 

52,510

 

 

 

(12.5)%

 

Battery Thermal Management (BTM)

 

 

8,897

 

 

 

7,241

 

 

 

22.9 %

 

 

 

19,641

 

 

 

11,402

 

 

 

72.3 %

 

Electronics

 

 

11,454

 

 

 

15,842

 

 

 

(27.6)%

 

 

 

24,306

 

 

 

31,819

 

 

 

(23.6)%

 

Other Automotive

 

 

9,050

 

 

 

6,311

 

 

 

43.4 %

 

 

 

18,817

 

 

11,734

 

 

 

60.4 %

 

Subtotal Automotive

 

$

229,700

 

 

$

243,150

 

 

 

(5.5)%

 

 

$

472,057

 

 

$

485,571

 

 

 

(2.8)%

 

Remote Power Generation (GPT)

 

 

3,745

 

 

 

5,270

 

 

 

(28.9)%

 

 

 

7,704

 

 

 

9,932

 

 

 

(22.4)%

 

Industrial Chambers

 

 

 

 

 

10,418

 

 

 

(100)%

 

 

 

3,418

 

 

 

20,631

 

 

 

(83.4)%

 

Gentherm Medical

 

 

9,881

 

 

 

7,562

 

 

 

30.7 %

 

 

 

18,068

 

 

 

14,852

 

 

 

21.7 %

 

Subtotal Industrial

 

$

13,626

 

 

$

23,250

 

 

 

(41.4)%

 

 

$

29,190

 

 

$

45,415

 

 

 

(35.7)%

 

Total Company

 

$

243,326

 

 

$

266,400

 

 

 

(8.7)%

 

 

$

501,247

 

 

$

530,986

 

 

 

(5.6)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Core Businesses (Automotive and Gentherm Medical)

 

$

239,581

 

 

$

250,712

 

 

 

(4.4)%

 

 

$

490,125

 

 

$

500,423

 

 

 

(2.1)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)Certain reclassifications of prior year’s amounts have been made to conform with the current year’s presentation

 

 

 

 

 

 


 


 

 

GENTHERM INCORPORATED

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

(In thousands)

(Unaudited)

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended

June 30,

 

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

Net Income

 

$

2,751

 

 

$

16,659

 

 

$

11,165

 

 

$

29,625

 

 

Add Back:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Income tax expense

 

 

5,548

 

 

 

3,083

 

 

 

12,443

 

 

 

6,119

 

 

     Interest expense

 

 

1,240

 

 

 

1,240

 

 

 

2,608

 

 

 

2,420

 

)

     Depreciation and amortization

 

 

11,094

 

 

 

12,859

 

 

 

22,074

 

 

 

25,679

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expenses

 

 

1,231

 

 

 

6,215

 

 

 

3,145

 

 

 

7,080

 

 

Impairment of assets held for sale

 

 

9,885

 

 

 

 

 

 

20,369

 

 

 

 

 

Gain on sale of business

 

 

 

 

 

 

 

 

(4,970

)

 

 

 

 

Acquisition transaction expenses

 

 

342

 

 

 

 

 

 

380

 

 

 

 

 

     Unrealized currency loss (gain)

 

 

71

 

 

 

(4,532

)

 

 

(923

)

 

 

(890

)

 

CFO transition expense

 

 

 

 

 

 

 

 

1,065

 

 

 

 

 

Adjusted EBITDA

 

$

32,162

 

 

$

35,524

 

 

$

67,356

 

 

$

70,033

 

 

 

Use of Non-GAAP Financial Measures

 

In addition to the results reported in accordance with GAAP throughout this release, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company’s reconciliation of net income to Adjusted EBITDA is provided in this release. The Company’s Reconciliation of Adjusted EPS can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated July 25, 2019 and also is included in the presentation entitled “Q2 2019 Gentherm Incorporated Earnings Conference Call Release,” which can be found on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.

 


 

 

 

Non-GAAP measures referenced in this release may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.

 

 

 

 

 


 


 

 

GENTHERM INCORPORATED

ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS

AND OTHER EFFECTS

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

 

June 30,

 

 

Future Full Year Periods (estimated)

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

2019

2020

 

 

2021

 

 

2022

 

 

Thereafter

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction related current expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition transaction expenses

 

$

342

 

 

$

 

 

$

380

 

 

$

 

 

$      380

$

 

$

 

 

 

$

 

$

 

 

 

Non-cash purchase accounting impacts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships amortization

 

 

1,936

 

 

 

2,607

 

 

 

3,764

 

 

 

5,273

 

 

7,677

 

6,569

 

 

 

6,003

 

 

 

5,581

 

 

 

20,905

 

 

Technology amortization

 

 

498

 

 

 

985

 

 

 

980

 

 

 

1,791

 

 

1,986

 

2,012

 

 

 

2,004

 

 

 

1,945

 

 

 

5,063

 

 

Inventory fair value adjustment

 

 

117

 

 

 

30

 

 

 

156

 

 

 

59

 

 

462

 

447

 

 

 

 

 

 

 

 

 

 

 

Other effects

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expenses

 

 

1,231

 

 

 

6,276

 

 

 

3,145

 

 

 

7,141

 

 

3,145

 

 

 

 

 

 

 

 

 

 

 

 

Gain on sale of business

 

 

 

 

 

 

 

 

(4,970

)

 

 

 

 

(4,970)

 

 

 

 

 

 

 

 

 

 

 

 

Impairment loss

 

 

9,885

 

 

 

 

 

 

20,369

 

 

 

 

 

20,369

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized currency loss (gain)

 

 

71

 

 

 

(4,532)

 

 

 

(923

)

 

 

(890

)

 

(923)

 

 

 

 

 

 

 

 

 

 

 

 

CFO Transition

 

 

 

 

 

 

 

 

1,065

 

 

 

 

 

1,065

 

 

 

 

 

 

 

 

 

 

 

 

Total acquisition transaction expenses, purchase accounting impacts and other effects

 

$

14,080

 

 

$

5,366

 

 

$

23,966

 

 

$

13,374

 

 

 

 

$ 29,191

$

9,028

 

 

$

8,007

 

 

$

7,526

 

 

$

 

 

25,968

 

 

Tax effect of above

 

 

(1,117

)

 

 

(711)

 

 

 

(905

)

 

 

(2,452

)

 

(2,236)

 

(2,313

)

 

 

(2,037

)

 

 

(1,914

)

 

 

(6,571)

 

 

Net income effect

 

$

12,963

 

 

$

4,655

 

 

$

23,061

 

 

$

10,922

 

 

$26,955

$

6,715

 

 

 

5,970

 

 

 

5,612

 

 

$

19,397

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share - difference

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.39

 

 

$

0.12

 

 

$

0.69

 

 

$

0.30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.39

 

 

$

0.13

 

 

$

0.69

 

 

$

0.30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.47

 

 

$

0.58

 

 

$

1.02

 

 

$

1.11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.47

 

 

$

0.58

 

 

$

1.02

 

 

$

1.11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 


 

 

GENTHERM INCORPORATED

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

 

 

June 30,
2019

 

 

December 31,
2018

 

ASSETS

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

33,677

 

 

$

39,620

 

Restricted cash

 

2,504

 

 

 

 

Accounts receivable, less allowance of $1,399 and $851, respectively

 

171,640

 

 

 

166,858

 

Inventory:

 

 

 

 

 

 

 

Raw materials

 

66,181

 

 

 

61,679

 

Work in process

 

6,660

 

 

 

5,939

 

Finished goods

 

39,772

 

 

 

44,917

 

Inventory, net

 

112,613

 

 

 

112,535

 

Derivative financial instruments

 

1,155

 

 

 

92

 

Prepaid expenses and other assets

 

50,128

 

 

 

54,271

 

Assets held for sale

 

6,714

 

 

 

69,699

 

Total current assets

 

378,431

 

 

 

443,075

 

Property and equipment, net

 

169,345

 

 

 

171,380

 

Goodwill

 

65,114

 

 

 

55,311

 

Other intangible assets, net

 

55,479

 

 

 

56,385

 

Operating lease right-of-use assets

 

13,267

 

 

 

 

Deferred financing costs

 

1,782

 

 

 

647

 

Deferred income tax assets

 

60,071

 

 

 

64,024

 

Other non-current assets

 

8,421

 

 

 

12,225

 

Total assets

$

751,910

 

 

$

803,047

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

Accounts payable

$

84,009

 

 

$

93,113

 

Accrued liabilities

 

62,706

 

 

 

65,808

 

Current lease liabilities

 

5,031

 

 

 

 

Current maturities of long-term debt

 

2,955

 

 

 

3,413

 

Liabilities held for sale

 

6,714

 

 

 

13,062

 

Total current liabilities

 

161,415

 

 

 

175,396

 

Pension benefit obligation

 

6,765

 

 

 

7,211

 

Non-current lease liabilities

 

7,741

 

 

 

 

Long-term debt, less current maturities

 

104,393

 

 

 

136,477

 

Deferred income tax liabilities

 

2,577

 

 

 

1,177

 

Other non-current liabilities

 

3,738

 

 

 

3,087

 

Total liabilities

 

286,629

 

 

 

323,348

 

Shareholders’ equity:

 

 

 

 

 

 

 

Common Stock:

 

 

 

 

 

 

 

No par value; 55,000,000 shares authorized, 33,147,567 and 33,856,629 issued and outstanding at June 30, 2019 and December 31, 2018, respectively

 

 

115,310

 

 

 

140,300

 

Paid-in capital

 

14,020

 

 

 

14,934

 

Accumulated other comprehensive loss

 

(39,440

)

 

 

(39,500

)

Accumulated earnings

 

375,391

 

 

 

363,965

 

Total shareholders’ equity

 

465,281

    

 

 

479,699

 

Total liabilities and shareholders’ equity

$

751,910

 

 

$

803,047

 


 


 

 

GENTHERM INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

Six Months Ended June 30,

 

 

2019

 

  

2018

 

Operating Activities:

 

 

 

 

 

 

 

Net income

$

11,165

 

 

$

29,625

 

Adjustments to reconcile net income to cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

22,217

 

 

 

25,823

 

Deferred income taxes

 

3,070

 

 

 

(1,799

)

Stock compensation

 

3,291

 

 

 

4,063

 

Defined benefit plan income

 

(699

)

 

 

(103

)

Provision of doubtful accounts

 

545

 

 

 

204

 

Loss on sale of property and equipment

 

227

 

 

 

2,156

 

Operating lease expense

 

2,903

 

 

 

 

Impairment loss

 

20,369

 

 

 

 

Gain on sale of business

 

(4,970

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(4,021

)

 

 

(17,469

)

Inventory

 

1,650

 

 

 

1,631

 

Prepaid expenses and other assets

 

276

 

 

 

(12,094

)

Accounts payable

 

(9,528

)

 

 

10,540

 

Accrued liabilities

 

(6,087

)

 

 

(10,034

)

Net cash provided by operating activities

 

40,408

 

 

 

32,543

 

Investing Activities:

 

 

 

 

 

 

 

Proceeds from the sale of property and equipment

 

82

 

 

 

698

 

Proceeds from sale of a business

 

47,500

 

 

 

 

Acquisition of subsidiary, net of cash acquired

 

(15,476

)

 

 

(15

)

Purchases of property and equipment

 

(13,024

)

 

 

(22,138

)

Net cash provided by (used in) investing activities

 

19,082

 

 

 

(21,455

)

Financing Activities:

 

 

 

 

 

 

 

Borrowing of debt

 

28,371

 

 

 

15,000

 

Repayments of debt

 

(61,120

)

 

 

(46,742

)

Cash paid for financing costs

 

(1,278

)

 

 

 

Cash paid for the cancellation of restricted stock

 

(926

)

 

 

(882

)

Proceeds from the exercise of Common Stock options

 

4,771

 

 

 

4,966

 

Repurchase of Common Stock

 

(33,040

)

 

 

(20,241

)

Net cash used in financing activities

 

(63,222

)

 

 

(47,899

)

Foreign currency effect

 

293

 

 

 

(1,004

)

Net decrease in cash, cash equivalents and restricted cash

 

(3,439

)

 

 

(37,815

)

Cash, cash equivalents and restricted cash at beginning of period

 

39,620

 

 

 

103,172

 

Cash, cash equivalents and restricted cash at end of period

$

36,181

 

 

$

65,357

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

Cash paid for taxes

$

3,522

 

 

$

18,100

 

Cash paid for interest

$

2,712

 

 

$

2,608

 

Supplemental disclosure of non-cash transactions:

 

 

 

 

 

 

 

Common Stock issued to Board of Directors and employees

$

3,605

 

 

$

2,419

 

 

# # # #

 

 

thrm-ex992_264.pptx.htm

Slide 1

2019 Second Quarter Results Gentherm, Inc. July 25, 2019 Exhibit 99.2

Slide 2

Forward-Looking Statement Except for historical information contained herein, statements in this presentation are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this presentation are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs.  Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, new competitors may arise or customers may develop their own products to replace the Company’s products, customer preferences for end products may shift, the Company may lose suppliers or customers, market acceptance of the Company’s existing or new products may decrease, currency exchange rates may change unfavorably, pricing pressures from customers may increase, current and projected future declines in automobile production may have an adverse impact, the macroeconomic environment may present adverse conditions, additional financing requirements may not be available, the Company’s workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, our customers may not accept pass-through of new tariff costs, additional tariffs may be implemented, cost-savings measures may not be achievable or may need to be reversed, assets held for sale may not be sold quickly or at all, the Company may be unable to repurchase its shares of common stock at favorable prices or at all, due to market conditions, applicable legal requirements, debt covenants or other restrictions, compliance with covenants and other restrictions under the Company’s credit facility, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results. You should review the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent quarterly reports, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this presentation does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof.  Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Slide 3

In addition to the results reported in accordance with GAAP throughout this presentation, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Non-GAAP measures referenced in this presentation may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods. * See Appendix for a reconciliation of GAAP to non-GAAP financial measures Use of Non-GAAP Financial Measures*

Slide 4

2Q 2019 Highlights Continued progress on Focused Growth and margin expansion activities Significantly outperformed the Automotive market Continued Automotive awards momentum Strong double-digit revenue growth in Medical Achieved highest Gross Margin rate in 5 quarters Reduced Operating Expenses by 14 percent $25M of share repurchases in the quarter

Slide 5

20 Vehicle launches with 11 OEMs Multiple CCS® product launches SAICFAW Kia Innovative multifunction Electronic Control Unit launch Ford Explorer Lincoln Aviator New and follow on ClimateSenseTM development projects with luxury German and U.S. automakers Consistently outperforming the Automotive market and exceeding customers’ expectations Automotive 2Q 2019 Highlights

Slide 6

$260M in awards across 23 OEMs Multiple CCS® awards Jeep CompassBuick Enclave BMW 7-SeriesChevrolet Traverse CCS® Active award for BMW 7-Series Steering Wheel Heater awards across 15 OEMs Air cooling Battery Thermal Management award First award with Renault – Seat Heater and Electronics Automotive 2Q 2019 Awards Strategic technology awards position Gentherm for long-term growth

Slide 7

Industrial 2Q 2019 Highlights Well positioned to grow the Medical business Double-digit revenue growth in Medical year over year Higher-than-expected demand for newly-acquired Stihler products Continued strong growth in Blanketrol® equipment and consumables with largest contribution from Asia Received initial orders for UV TREO, our new cardiovascular heat/cool system with integrated disinfection technology

Slide 8

Selected Income Statement Data Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (In thousands, except per share data) Product Revenues $ 243,326 $ 266,400 $ 501,247 $ 530,986 Gross Margin 72,714 77,092 148,021 158,334 Gross Margin % 29.9% 28.9% 29.5% 29.8% Operating Expenses 52,657 61,499 106,119 122,092 Operating Income 20,057 15,593 41,902 36,242 Adjusted EBITDA 32,162 35,524 67,356 70,033 Adjusted EPS 0.47 0.58 1.02 1.11

Slide 9

Selected Balance Sheet Data June 30, 2019 December 31, 2018 (In thousands) Cash, Cash Equivalents and Restricted Cash $ 36,181 $ 39,620 Total Assets 751,910 803,047 Debt 107,348 139,890 Current 2,955 3,413 Non-Current 104,393 136,477 Revolving LOC Availability 378,533 221,871 Total Liquidity 414,714 261,491

Slide 10

2019 Guidance 2019E Revenue Growth 0% - 2% Gross Margin 29% - 30% Operating Expenses % of Revenue 19% - 20% Adjusted EBITDA Margin (1) 14% - 15% Updating 2019 Revenue and Gross Margin Guidance (1) Due to the inherent difficulty of forecasting the timing and amount of certain items that would impact net income, such as foreign currency gains and losses, we are unable to reasonably estimate net income, the GAAP financial measure most directly comparable to Adjusted EBITDA. Accordingly, we are unable to provide a reconciliation of Adjusted EBITDA to net income with respect to the guidance provided.

Slide 11

Slide 12

Appendix

Slide 13

Reconciliation of Net Income to Adjusted EBITDA Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018   (In thousands) Net Income $ 2,751 $ 16,659 $ 11,165 $ 29,625 Add Back: Income Tax Expense 5,548 3,083 12,443 6,119 Interest Expense 1,240 1,240 2,608 2,420 Depreciation and Amortization 11,094 12,859 22,074 25,679 Adjustments: Restructuring Expenses 1,231 6,215 3,145 7,080 Impairment of Assets Held for Sale 9,885 - 20,369 - Gain on Sale of a Business - - (4,970) - Acquisition Transaction Expense 342 - 380 - Unrealized Currency Loss (Gain) 71 (4,532) (932) (890) CFO Transition Expenses - - 1,065 - Adjusted EBITDA $ 32,162 $ 35,524 $ 67,356 $ 70,033

Slide 14

Reconciliation of Adjusted EPS (1) Certain reclassifications of prior year’s amounts have been made to conform with the current year’s presentation. Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Diluted EPS - As Reported $ 0.08 $ 0.45 $ 0.33 $ 0.81 Acquisition Transaction Expenses 0.01 - 0.01 - Non-Cash Purchase Accounting Impacts 0.08 0.10 0.15 0.19 Unrealized Currency (Gain)/Loss - (0.12) (0.03) (0.02) Restructuring Expenses 0.04 0.17 0.09 0.19 Gain on Sale of a Business - - (0.15) - Impairment Losses 0.29 - 0.61 - CFO Transition Expense - - 0.03 - Tax Effect of Above (0.03) (0.02) (0.03) (0.07) Rounding Adjustment - - - 0.01 Diluted EPS - As Adjusted $ 0.47 $ 0.58 $ 1.02 $ 1.11